EU widens GSK's Arixtra label
This article was originally published in Scrip
Executive Summary
The European Commission has extended the label for GlaxoSmithKline's Factor Xa inhibitor Arixtra (fondaparinux). The drug is now the first anti-clotting agent to be indicated for treating adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.